Dr Reddys Laboratories Ltd (DRREDDY) Q1 FY27 Results Analysis: PAT Plunges 69%, Gross Margin Compresses 1,039 bps

Dr Reddys Laboratories Ltd's Q1 FY27 numbers came in soft, with revenue of Rs. 8,070.50 Cr (-5.60% YoY) and PAT growth of -68.70% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

Dr. Reddy's Q1 FY27 results were sharply lower than the prior year, with revenue declining 5.6% YoY and PAT plunging 68.7%, dragged by lower lenalidomide sales and a Rs.239.7 Cr semaglutide provision. Gross margin compression of 1,039 bps and EBITDA margin of 12.5% (well below the 25% FY27 target) highlight significant earnings pressure. The company missed multiple guidance targets, and while the base business ex-lenalidomide grew double-digit, the near-term outlook remains challenging with the semaglutide supply halt and regulatory observations.

Key Investment Insights

Key Positives

• India revenue grew 16.8% YoY, within the 15-16% sustainable guidance range.
• Emerging Markets revenue grew 30.5% YoY, driven by new launches and favourable forex.
• Europe revenue grew 13.3% YoY, supported by new generic launches.
• Base business (excluding lenalidomide) delivered double-digit growth across all geographies per management.
• Launched Bosutinib in the US with first-to-market 180-day exclusivity.
• India secondary sales grew 14.6% (MQT) vs IPM 13.5%, indicating market share gain.

Risk Factors

• Revenue declined 5.6% YoY and PAT plunged 68.7% YoY, driven by lower lenalidomide sales and a Rs.239.7 Cr semaglutide provision.
• Gross margin compressed 1,039 bps YoY to 46.5%, and EBITDA margin fell 1,420 bps YoY to 12.5%.
• SG&A expenses rose 12.4% YoY, missing the flat nominal guidance for FY27.
• Operating cash flow was weak at Rs.101.5 Cr, only 23% of PAT, and free cash flow was negative Rs.215.8 Cr.
• Borrowings increased 48% YoY to Rs.7,195.2 Cr, and the company received an FDA Form 483 with 7 observations at the Bachupally biologics facility.